semaglutide lowers blood pressure via GLP-1 receptors on vascular smooth muscle, not via endothelial or immune pathways. There is a direct vasorelaxant mechanism linking GLP-1R activation to BP and… Semaglutide Lowers Cardiovascular Risks But

Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update

By helping clients manage hunger signals more effectively, GLP-1 medications support long-term adherence to healthy eating and exercise routines

While sterile technique and single-use needles minimize infection risk, any breach in skin integrity creates potential for bacterial entry

The STEP 1 trial followed 1,961 adults for 68 weeks on semaglutide 2.4mg

In a two-year trial Advertisement funded by Novo Nordisk, participants with type 2 diabetes and a high cardiovascular risk reported more events of diabetic retinopathy complications while taking semaglutide compared to those on a placebo